Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the safety and efficacy of losmapimod in treating patients with
Facioscapulohumeral Muscular Dystrophy (FSHD) over 48 weeks.